Genomic Blueprint: How Next-Generation Sequencing is Revolutionizing Cancer Care in India

June 22, 2026 | Bikaner, India

When stage-4 lung cancer metastasized to her brain, leaving her unable to walk and suffering from violent convulsions, 80-year-old Sita Devi (name changed) faced a grim prognosis. Living in rural Rajasthan, traditional protocols offered her little more than palliative care. However, a modern diagnostic tool altered her trajectory entirely. Nearly a year after undergoing a advanced genomic test known as next-generation sequencing (NGS), Devi walks independently and routinely attends her follow-up appointments unassisted.

Devi’s recovery highlights a profound medical shift accelerating through India’s healthcare system. Next-generation sequencing, the newest frontier in medical diagnostics, is fundamentally changing cancer care by decoding deep genomic data and allowing oncologists to design highly personalized treatment strategies within days rather than weeks.

Precision Medicine Delivers Tangible Results

The impact of NGS extends far beyond individual anecdotes. Driven by public-private collaborations, precision oncology—treating a disease based on a patient’s specific genetic profile—is scaling rapidly across India.

Since March 2025, a collaborative initiative called the LuNGS Alliance—uniting oncologists, government institutions, startups, and pharmaceutical companies—has provided free NGS testing to more than 6,600 lung cancer patients spanning 700 cities and towns. The clinical findings have been remarkably clear:

• Actionable Alterations: An impressive 58% of tested patients exhibited specific genetic mutations that directly informed treatment decisions. This means more than one in two patients could potentially benefit from targeted therapies rather than broad-spectrum chemotherapy.

• Treatment Access: In a follow-up cohort of 1,920 patients, 45% successfully transitioned to biomarker-directed, precision-based therapies.

• Diagnostic Efficiency: The financial and operational efficiency of the technology has evolved rapidly. In 2015, identifying just four biomarkers required four separate tests and cost over ₹20,000. Today, for that same price, an NGS panel can evaluate a minimum of 50 genetic mutations simultaneously.

Decoding the Technology: How NGS Shifts the Paradigm

Traditional diagnostics often look at cancer cells under a microscope to determine their tissue origin. In contrast, NGS evaluates the underlying software of the disease. The process begins with a biological sample—typically a tissue biopsy, blood draw, or saliva sample.

This sample is processed using automated sequencing machines that rapidly read millions to billions of DNA base pairs, constructing a precise digital map of the patient’s genes. By cross-referencing this map against known cancer mutations, pathologists can pinpoint the exact genetic anomalies driving tumor growth.

Without these detailed insights, oncologists frequently have to rely on empirical trials, prescribing broad therapies that may not effectively target the tumor or could subject the patient to unnecessary toxicities. By exposing the specific drivers of a disease, NGS enables clinicians to understand exact causes, evaluate inherited genetic risks, and accurately predict how a patient will respond to specific medications.

Inside India’s Unique Mutation Landscape

A landmark study published in JCO Global Oncology analyzed comprehensive genomic profiling data from 5,219 Indian lung cancer patients. The data revealed a critical epidemiologic reality: the genetic architecture of cancers in Indian patients differs significantly from Western demographics.

+------------------------------------+--------------------+-------------------+
| Mutation Type                      | Western Population | Indian Population |
+------------------------------------+--------------------+-------------------+
| EGFR (Lung Cancer Overall)         | 10% - 15%          | 34.1% - 35%       |
| KRAS (Non-Small Cell Lung Cancer)  | ~25%               | ~10%              |
| TP53 (Tumor Suppressor Alteration) | Not Specified      | 37%               |
| Total Actionable Alterations       | Not Specified      | 64.2%             |
+------------------------------------+--------------------+-------------------+

Overall, genomic alterations were detected in 80.6% of the Indian cohort, with 64.2% hosting actionable mutations that map to therapies approved by regulatory agencies like the U.S. Food and Drug Administration (FDA).

Medical oncology experts note that global clinical trial data for new oncology medications historically underrepresents Indian populations. Given that Southeast Asia, West Asia, and the Indian subcontinent contribute to over half of the world’s annual cancer incidences—amounting to roughly 10 million new cases—establishing indigenous genomic databases is essential for effective regional public health strategies.

Transforming Daily Oncology Practice

For clinicians on the ground, these genetic variations translate directly into tailored treatment selections. Dr. Surendra Beniwal, a medical oncologist at the Acharya Tulsi Regional Cancer Institute and Research Centre in Bikaner, managed Sita Devi’s case using these insights.

“Devi presented with an EGFR mutation [a mutation in the epidermal growth factor receptor protein], which pinpointed the use of a drug that targeted exactly that,” Dr. Beniwal explained. Instead of undergoing standard, systemic chemotherapy regimens involving drugs like carboplatin or paclitaxel—which carry severe side effects, particularly for elderly patients—Devi was prescribed a single daily targeted tablet of osimertinib.

Dr. Beniwal observed a similar success story in a 24-year-old woman diagnosed with stage-2 breast cancer. “Because of NGS and targeted treatment, she could be spared from multiple complications of chemotherapy, expensive antibiotics, and neutropenia, which leads to low immunity,” he noted. Today, she leads a healthy, normal life.

This shifting philosophy is gaining traction across the wider medical community. Healthcare innovators emphasize that the future of chronic disease management will rely less on uniform, mass-produced blockbusters and more on deep data analysis, matching the right patient to the exact right treatment by analyzing variables from DNA to regional demographics.

Public Health Implications: Tackling Late-Stage Diagnoses

The clinical scaling of NGS arrives at a critical juncture for Indian public health. Lung cancer accounts for nearly 10% of all cancer-related deaths across the country. Data from the Global Cancer Observatory indicates that India sees approximately 81,000 new lung cancer cases annually, with nearly two-thirds of diagnosed patients succumbing to the disease within two years.

Furthermore, India has the third-highest cancer burden globally, a statistic compounded by the fact that over 80% of cases are diagnosed at an advanced stage. Implementing data-driven precision diagnostics early in the care pathway offers a vital opportunity to improve these survival rates.

Crucially, modern diagnostic initiatives are successfully penetrating beyond major metropolitan healthcare centers. Over 60% of the genomic samples processed by the LuNGS Alliance originated from tier-2 and tier-3 cities. Rajasthan led this regional distribution, contributing 858 samples and demonstrating that advanced molecular diagnostics can be successfully integrated into smaller municipalities.

Economic Realities and Implementation Barriers

Despite significant technological advancements, substantial economic hurdles remain. While basic NGS panels in India have dropped to approximately ₹20,000, extensive, high-end pan-cancer screenings can still reach up to ₹4 lakh. Though these costs are substantially lower than the $4,000 to $5,000 fees common in Western nations, they remain out of reach for a large portion of the Indian public.

However, diagnosing the mutation is only the first step; accessing the corresponding treatment presents an even greater financial challenge. The market prices for standard targeted therapies and immunotherapies remain highly prohibitive for average consumers:

• Osimertinib (AstraZeneca’s Tagrisso): Approximately ₹1.2 to ₹1.4 lakh for a 10-tablet supply.

• Durvalumab (Imfinzi): Approximately ₹1.4 lakh per vial.

• Nivolumab (Opdivo): Approximately ₹1 lakh per vial.

• Domestic Generics (e.g., Zydus Lifesciences’ Tishtha): Priced at roughly one-fourth of the innovator cost, though still a major financial commitment for many families.

Public health advocates stress that improving patient access to molecular testing must be accompanied by parallel efforts to make the required precision medicines affordable. Without affordable therapeutics, the clinical utility of advanced diagnostics cannot be fully realized.

Limitations and Contradictory Evidence

While the benefits of genomic testing are significant, the technology is not a universal solution. An observational study published in the Journal of Clinical Oncology monitored 126 patients with advanced malignancies and identified clear boundaries to the real-world utility of NGS.

The study concluded that NGS testing did not significantly improve clinical outcomes for patients experiencing rapid clinical progression, those with poor baseline performance status, or individuals facing severe financial limitations. Notably, within that study’s cohort, even when actionable pathogenic targets were successfully identified, financial constraints prevented the initiation of the appropriate targeted therapies.

Additionally, the cost-effectiveness of these interventions varies widely depending on the cancer type. Health economics data shows that while precision testing for colorectal cancer costs roughly $59,000 per person-year of life saved, that figure can climb toward $500,000 per person-year saved in less responsive or more complex malignancies. Clinicians also note that internal demographic variations across India mean mutation patterns in the Northeast could differ substantially from those in southern states, requiring much more comprehensive regional mapping before universal protocols can be established.

The Road Ahead: Market Growth and Broader Applications

Looking forward, the commercial infrastructure supporting genomic medicine in India is positioned for significant growth. Industry projections indicate that India’s genome sequencing market will reach $1.5 billion by 2030, driven by a 27% compound annual growth rate (CAGR). Concurrently, the broader Indian precision medicine sector is projected to expand fivefold, reaching an estimated $5.8 billion.

Major healthcare networks are preparing for this shift. Apollo Hospitals currently operates dedicated genomics institutes across 12 Indian cities, with six more facilities in active development. Global biotechnology suppliers, including market leader Illumina, anticipate their Indian business segments will expand three- to fivefold over the next seven years.

Diagnostic experts anticipate that as NGS transitions into routine histopathology workflows for standard tissue biopsies, costs will decline further. Furthermore, the potential inclusion of NGS panels within public healthcare frameworks, such as the central government’s Ayushman Bharat insurance scheme, could catalyze widespread adoption at the grassroots level.

Finally, the clinical utility of NGS is expanding well beyond oncology. Diagnostics professionals note that oncology and neurology represent the two fastest-growing disease segments globally for sequencing applications. The technology is increasingly utilized to diagnose rare pediatric genetic disorders, guide complex high-risk pregnancies, and direct urgent interventions in neonatal intensive care units. By scanning a patient’s entire genome, clinicians can isolate single point mutations responsible for complex, idiopathic symptoms, marking a definitive shift toward a data-driven era of medicine.

Medical Disclaimer

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References

• https://health.economictimes.indiatimes.com/news/diagnostics/scanning-cancer-up-close-personal-a-revolution-is-underway-in-cancer-diagnosis/131885778?utm_source=top_story&utm_medium=homepage